| Abstrakt: |
A study conducted by the American University of Beirut examined the effectiveness of new biologics in managing postoperative Crohn's disease. The research found that vedolizumab and ustekinumab showed promising results, but more controlled studies are needed to compare them with anti-tumor necrosis factor agents. While some studies indicated comparable recurrence rates with the use of newer biologics and anti-tumor necrosis factor agents, others did not show their efficacy conclusively. The researchers suggested an updated algorithm for the role of newer biologics in treating postoperative Crohn's disease, but emphasized the need for better-designed studies to determine their definitive positioning. [Extracted from the article] |
